Watch this webinar to learn how functional service providers (FSPs) are transforming the clinical research landscape by providing specialized skills, adaptable resources and cost-efficient solutions.
As drug development costs continue to escalate, sponsors need to find less expensive approaches to develop their assets. One way to be more cost-efficient is to outsource some areas of drug development. FSPs have reshaped clinical research by offering specialized skills and adaptable resources.
As trials become more complex, many biotech and biopharma companies are opting for FSPs over full-service outsourcing. FSPs provide numerous advantages such as globalized strategies, expert domain knowledge and efficient management, thus helping balance quality, innovation and cost.
Sponsors engage FSP models when seeking efficiencies. FSP models provide increased operational and resourcing flexibility and different pricing plans in comparison to traditional full-service clinical research organization (CRO) offerings. FSPs deliver capabilities across a broad base, including subject matter experts in the functional areas, which helps accelerate drug development and decrease overall costs.
A sponsor should feel a true partnership with an adaptable provider willing to help achieve high-quality, cost-effective results as clinical trials are becoming complex and require specific expertise.
Watch today to learn about the strategic advantages, including expert domain knowledge, global strategies and operational flexibility, for biotech and biopharma companies in engaging functional service providers for drug development.
The panelists:
- Melissa Church, SVP, Strategy & Solutions, Catalyst Clinical Research (Moderator)
- Craig McIlloney, SVP, Catalyst Flex, Catalyst Clinical Research
- Rob Petrie, Chief Innovation Officer, OrciMed Life Sciences
- Elisha Talley-Roithner, Head of Operations, Launch Therapeutics
